Safety Profile, Infection Mitigation, and Community Practice Integration of Linvoseltamab

Drs Paul Richardson and Hans Lee focus on the safety profile of linvoseltamab and how its clinical features translate into real-world and community-based practice. The discussion reviews rates of neurotoxicity, cytopenias, cytokine release syndrome, and infections observed in the LINKER-MM1 study, highlighting the generally low incidence of high-grade events and the importance of proactive infection mitigation strategies such as antiviral and PJP prophylaxis and IVIg use. Dr Lee explains how the study’s planned de-escalation of dosing frequency may help reduce cumulative infection risk over time. The faculty also examine practical considerations that are particularly relevant in community settings, including the intravenous route of administration, step-up dosing cadence, and limited inpatient observation requirements. Together, they discuss how these factors support feasibility outside of large academic centers, facilitate coordination with community partners, and improve patient convenience. This segment underscores how safety, logistics, and dosing flexibility play a central role in integrating BCMA-directed bispecific therapies into everyday myeloma care.